Phenotype of SDHB mutation carriers in the Netherlands

In conclusion, the two main Dutch SDHB founder mutations do not differ in clinical expression and result in a relatively mild phenotype. Over one-third of SDHB mutation carriers develop HNPGL, with sPGL/PCC in only 15 % and malignancy in only 4 %.
Source: Familial Cancer - Category: Cancer & Oncology Source Type: research